Paradigm Biocapital Advisors LP Y M Abs Therapeutics, Inc. Transaction History
Paradigm Biocapital Advisors LP
- $1.95 Billion
- Q1 2025
A detailed history of Paradigm Biocapital Advisors LP transactions in Y M Abs Therapeutics, Inc. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 4,236,346 shares of YMAB stock, worth $21.6 Million. This represents 0.96% of its overall portfolio holdings.
Number of Shares
4,236,346
Previous 4,236,346
-0.0%
Holding current value
$21.6 Million
Previous $33.2 Million
43.42%
% of portfolio
0.96%
Previous 1.27%
Shares
4 transactions
Others Institutions Holding YMAB
# of Institutions
105Shares Held
27.1MCall Options Held
38.4KPut Options Held
2.1K-
Acorn Capital Advisors, LLC New York, NY3.24MShares$16.5 Million9.97% of portfolio
-
Black Rock Inc. New York, NY2.94MShares$15 Million0.0% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA2.19MShares$11.2 Million0.72% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.95MShares$9.93 Million0.0% of portfolio
-
Polar Capital Holdings PLC London, X01.83MShares$9.34 Million0.05% of portfolio
About Y-mAbs Therapeutics, Inc.
- Ticker YMAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,719,500
- Market Cap $223M
- Description
- Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...